This Article Abstract Full Text Full Text (PDF) View Online Appendix Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stone, P. H. Search for Related Content PubMed PubMed Citation Articles by Stone, P. H.

Antianginal Efficacy of Ranolazine When Added to Treatment With Amlodipine

The ERICA (Efficacy of Ranolazine in Chronic Angina) Trial

Peter H. Stone, MD, FACC^_*,_*, Nikolay A. Gratsiansky, MD, Alexey Blokhin, MD, I.-Zu Huang, MD, Lixin Meng, MS, MPH, for the ERICA Investigators

^_* Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
Center for Atherosclerosis, Institute of Physicochemical Medicine, Moscow, Russia
Outpatient Clinic of Medical Center of Russian Federation President's Management Department, Moscow, Russia
CV Therapeutics, Palo Alto, California.

View larger version (11K): [in a new window]   Figure 1 Study design. BID = twice a day; QD = once per day; RAN = ranolazine.

View larger version (18K): [in a new window]   Figure 2 Patient disposition throughout the trial.

View larger version (30K): [in a new window]   Figure 3 Number of weekly angina attacks (A) and number of weekly nitroglycerin uses (B), excluding patients with weekly angina rate in the top 2% and bottom 2% of each treatment group (trimmed mean). SE = standard error of the trimmed mean.

View larger version (32K): [in a new window]   Figure 4 Number of weekly angina attacks (A) and change from baseline in Seattle Angina Questionnaire (SAQ) angina frequency domain scores (B) for patients with baseline median angina attack rates of 4.5 and >4.5 per week within each treatment group (trimmed mean).